EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

MyCODE : a prospective evaluation of lay-language molecular tumor board protocols in precision oncology

Ina Pretzell iD, Anke Fleischhauer, Ilektra Mavroeidi, Nicola Prasuhn, Katharina Kaminski, Noëlle Bender, Viktor Grünwald, Jessica Holly, Tina Hörbelt-Grünheidt, Tabea Pakull, Vivian Rosery, Hendrik Schürmann und 7 weitere

The Oncologist · 10.04.2026 · 31 (5)

DOI: 10.1093/oncolo/oyag119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 31.03.2026. Verfasst von Ina Pretzell und 18 weiteren Autor:innen. Beteiligte Einrichtung: West German Cancer Center (WTZ), University Hospital Essen, Essen 45147, Germany. Hauptthemen laut MEDLINE: Precision Medicine, Neoplasms, Medical Oncology. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Molecular Tumor Boards (MTBs) are a pillar of precision oncology, integrating results of extended molecular profiling into clinical care. Yet, their protocols are typically incomprehensible for patients. Systematic patient-facing communication has remained limited.

Methods

In the single-center study MyCODE, individually tailored lay-language MTB protocols were developed based on didactic and psychological principles and prospectively evaluated. Using questionnaires adapted and developed for this task, patients with cancer evaluated their individual protocols and overall experience. Treating physicians were surveyed separately.

Results

Forty-three patients were enrolled, 33 (77%; 55% women; median age 65; patients with 10 different cancer entities) returned completed questionnaires. Of those, 82% shared the questionnaire with at least one additional person. Lay-language protocols were perceived as helpful (68% “very,” 29% “rather”), well-structured (71% “very,” 29% “rather”), and easily comprehensible (63% “very,” 31% “rather”) by most patients. 85% reported that the protocol improved their understanding of treatment decisions, and 94% perceived them as supportive even if the MTB failed to provide options for precision therapy. Additionally, 13 treating physicians received questionnaires, of which 9 were returned. Responding physicians rated the benefit for patients as high (44%) or very high (44%) and supportive (67%) or rather supportive (33%) for their personal work.

Conclusions

Providing patients with lay-language MTB protocols is feasible, accepted, and valued even in the absence of therapeutic options. The MyCODE approach seems to enable patient empowerment and to support patients and physicians in shared decision-making in precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineNeoplasmsMedical OncologyHumansFemaleAgedSurveys and QuestionnairesMaleProspective StudiesMiddle AgedAdultPhysician-Patient Relations

Stichwörter der Autor:innen

lay-language summariesmolecular tumor boardpatient communicationpatient empowermentprecision medicineshared decision-making

Autor:innen und Institutionen

  • West German Cancer Center (WTZ), University Hospital Essen, Essen 45147, Germany.
  • Department of Medical Oncology, West German Cancer Center (WTZ), University Hospital Essen, Essen 45147, Germany.
  • Bridge Institute of Experimental Tumor Therapy (BIT), West German Cancer Center (WTZ), University Hospital Essen and University of Duisburg-Essen, Essen 45147, Germany.
  • Patient Advisory Board, West German Cancer Center (WTZ), University Hospital Essen, Essen 45147, Germany.
  • Social Psychology, Department of Human-Centered Computing and Cognitive Science, University of Duisburg-Essen, Duisburg 47057, Germany.
  • Institute for Urologic Oncology, West German Cancer Center (WTZ), University Hospital Essen, Essen 45147, Germany.

ORCID-Profile: Ina Pretzell, Sebastian Bauer, Dirk Schadendorf, Martin Schuler

Zitieren

APA

Pretzell, I., Fleischhauer, A., Mavroeidi, I., Prasuhn, N., Kaminski, K., Bender, N., Grünwald, V., Holly, J., Hörbelt-Grünheidt, T., Pakull, T., Rosery, V., Schürmann, H., Bauer, S., Siveke, J. T., Wiesweg, M., Zimmer, L., Schadendorf, D., Schuler, M., & Benson, S. (2026). MyCODE : a prospective evaluation of lay-language molecular tumor board protocols in precision oncology. The Oncologist, 31(5). https://doi.org/10.1093/oncolo/oyag119

Vancouver

Pretzell I, Fleischhauer A, Mavroeidi I, Prasuhn N, Kaminski K, Bender N, et al. MyCODE : a prospective evaluation of lay-language molecular tumor board protocols in precision oncology. The Oncologist. 2026;31(5). doi:10.1093/oncolo/oyag119

BibTeX
@article{Pretzell2026,
  author = {Pretzell, Ina and Fleischhauer, Anke and Mavroeidi, Ilektra and Prasuhn, Nicola and Kaminski, Katharina and Bender, Noëlle and Grünwald, Viktor and Holly, Jessica and Hörbelt-Grünheidt, Tina and Pakull, Tabea and Rosery, Vivian and Schürmann, Hendrik and Bauer, Sebastian and Siveke, Jens T and Wiesweg, Marcel and Zimmer, Lisa and Schadendorf, Dirk and Schuler, Martin and Benson, Sven},
  title = {MyCODE : a prospective evaluation of lay-language molecular tumor board protocols in precision oncology},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {5},
  doi = {10.1093/oncolo/oyag119}
}
Kostenlos starten →